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Abstract
Background: Unequivocal data presenting the impact of different pacing modes on B-type
natriuretic peptide levels has never been published. The aim of the study was to assess changes
of plasma B-type natriuretic peptide (BNP) during permanent cardiac pacing in patients with
sick sinus syndrome (SSS).
Methods: Patients with SSS undergoing routine pacemaker implantation were enrolled.
Each subject underwent medical history and examination, echocardiography and blood sampling.
Analysis was performed on 12 females (42.9%) and 16 males (57.1%), mean age 71.3 ± 9.03
years, range 49–90 years. There were 11 pacemakers with AAIR pacing mode (39.3%; AAI
group) and 17 with DDDR mode (60.7%; DDD group) implanted. There were no significant
differences in age, concomitant diseases or echocardiographic parameters between the groups
in baseline characteristics or plasma BNP levels (94.05 ± 54.1 vs. 73.57 ± 70.13 pg/mL; p > 0.2).
Results: During six months follow-up no significant changes in plasma BNP levels in AAI
group (94.05 ± 54.1 vs. 94.05 ± 54.1 pg/mL; p > 0.5) as well as in DDD group (73.57 ± 70.1
vs. 82.39 ± 58.9 pg/mL; p > 0.5) were noticed.
Conclusions: Atrial (AAIR) and dual chamber (DDDR) pacing did not influence plasma
BNP levels in patients with SSS and preserved left ventricular systolic function. (Cardiol J
2008; 15: 39–42)
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Introduction
Permanent cardiac pacing is a well-established
method of sick sinus syndrome (SSS) management.
Several studies are taking place to assess the influ-
ence of permanent pacing on cardiac hemodynamics
and its monitoring with natriuretic peptides [1]. The
results of certain trials concerning the impact of
different pacing modes in SSS on natriuretic pep-
tides concentration are equivocal or even divergent.
The aim of this study was to assess changes of plas-
ma B-type natriuretic peptide (BNP) levels during
permanent cardiac pacing in patients with sick
sinus syndrome.
Methods
The patients
The study group consisted of 12 females (42.9%)
and 16 males (57.1%) with SSS, aged 49–90 years
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(mean 71.3 ± 9.03). They underwent cardiac pacema-
ker implantation according to current guidelines [2].
The exclusion criteria were permanent atrial fibril-
lation, complete heart block, acute coronary syn-
drome six weeks prior to implantation, the presence
of inflammation, stroke three months prior to im-
plantation, hepatic or renal failure, heart failure in
II NYHA class or higher, neoplasia, respiratory in-
sufficiency regardless of cause, structural heart dis-
ease, connective tissue disease, storage disease,
muscular dystrophy and hemoglobin concentration
less than 10 g/dL. All participants were administered
beta-adrenolytics and angiotensine converting en-
zyme inhibitors due to ischemic heart disease and/or
arterial hypertension. Single- or dual-chamber pace-
makers were implanted (Axios, Biotronik) with
respect to atrio-ventricular conduction competence
rated by the measurement of the Wenckebach point
(atrial rhythm with atrio-ventricular block of second
degree) during the implantation procedure. Accord-
ing to the guidelines of the Polish Cardiac Society [2],
a dual-chamber pacemaker was implanted if the
Wenckebach rate was lower than 130 beats per
minute. The available algorithms of right ventricu-
lar pacing minimization were activated. The pacing
sites were the right atrial auricle and right ventricu-
lar apex. The basic clinical characteristics of the
study group are presented in Table 1. During six
months follow-up all subjects underwent physical
examination, echocardiographic evaluation, blood
sampling for BNP level measurements and pacing
trend assessment.
The local ethics committee approved the
study and informed consent was obtained from
each subject.
Echocardiographic evaluation
Prior to device implantation all subjects under-
went standard transthoracic echocardiographic
evaluation of the atria and ventricles with left ven-
tricular function assessment. Additional echocardi-
ographic exams were performed three and six
months after implantation to obtain the left atrial
size. Echocardiography was performed with an
ACUSON Sequoia C 256 system using a 3.5 MHz
transducer in the second harmonic mode. Measure-
ments were performed in parasternal long axis pro-
jection in M-mode. Left ventricular ejection frac-
tion was obtained by the Simpson method.
Plasma BNP level measurements
Plasma BNP levels were assessed three times
in each subject (prior to implantation and three and
six months after the procedure) with a AxSYM BNP
microparticle enzyme immunoassay (Abbott Labora-
tories). Venous blood sample for a single BNP meas-
urement was taken after a 15 minute rest in supine
position and stored in a cooled test-tube with EDTA.
Statistical analysis
Continuous variables are presented as mean ±
± standard deviation. The significance of the dif-
ferences between means was tested with the t-Stu-
dent test. Categorical variables were assessed with
the chi-square test. A p value of less than 0.05 was
considered significant.
Results
Patients were divided into two groups accord-
ing to pacing mode. The AAIR mode was applied in
11 subjects (39.3%; AAI group), and the DDDR
mode in 17 subjects (60.7%; DDD group). There
were no significant differences in age (72.4 ± 10.1
vs. 70.5 ± 8.53; p > 0.5), arterial hypertension:
10 (90.9%) in the AAI group vs. 15 (88.2%) in the DDD
group (p > 0.6) or paroxysmal atrial fibrillation:
5 (45.5%) in the AAI group vs. 10 (58.8%) in the
DDD group (p > 0.6). There was a borderline sig-
nificance in ischemic heart disease occurrence:
5 (45.5%) in the AAI group vs. 13 (76.5%) in the
DDD group (p > 0.05). There were no significant
differences between groups in echocardiographic
parameters of left ventricular function or dimen-
sions of the atria and ventricles. The mean plasma
BNP level prior to implantation in the AAI group did
not differ significantly from the level in the DDD group
(94.05 ± 54.1 vs. 73.57 ± 70.13 pg/mL; p > 0.2).
There were no significant changes in plasma BNP
Table 1. Baseline characteristics.
Total AAI DDD
(n = 28)  (n = 11)  (n = 17)
Age (years) 71.3±9.03 72.4±10.1 70.5±8.53
Females 12 (42.9%) 6 (54.5%) 6 (35.3%)
Males 16 (57.1%) 5 (45.5%) 11 (64.7%)
AH 25 (89.3%) 10 (90.9%) 15 (88.2%)
PAF 15 (53.6%) 5 (45.5%) 10 (58.8%)
IHD 18 (64.3%) 5 (45.5%) 13 (76.5%)
LVEDD [mm] 51±12 54±6,1 49±15
LVESD [mm] 34±4.9 35±4.9 34±5
LA [mm] 37±5.2 35±5 38±5.3
LVEF (%) 55±8 55±8 54±9
AH — arterial hypertension, PAF — paroxysmal atrial fibrillation,
IHD — ischemic heart disease, LVEDD — left ventricular end-diastolic
diameter, LVESD — left ventricular end-systolic diameter, LA — left
atrial area in M-mode, LVEF — left ventricular ejection fraction;
differences between groups are insignificant
41
Marcin Sadowski and Beata Wożakowska-Kapłon, BNP and permanent cardiac pacing
www.cardiologyjournal.org
levels in the six months follow-up in the AAI group
(94.05 ± 54.1 vs. 82.94 ± 79.9 pg/mL; p > 0.5)
or in the DDD group (73.57 ± 70.1 vs. 82.39 ±
± 58.9 pg/mL; p > 0.5) (Table 2). The baseline left
atrial size was 35.1 ± 4.9 mm in the AAI group and
37.9 ± 5.3 mm in the DDD group. No significant
changes were observed after six months (39.2 ±
± 3.1 mm and 41.1 ± 10.5, respectively). The per-
centage of pacing in the AAI group was from 3% to
97% (mean 52 ± 50.9). In the DDD group the per-
centage of atrial pacing was from 34% to 74% (mean
59.8 ± 13.9), and the percentage of ventricular pac-
ing was from 19% to 100% (mean 60.8 ± 34.5). There
was no significant difference between the percent-
ages of atrial pacing between the groups (p > 0.5).
Discussion
Natriuretic peptides are neurohormones that
play an important role in fluid homeostasis and va-
soconstriction due to their antagonistic action to-
wards the renin-angiotensin-aldosterone system.
They are also crucial to vascular function and re-
modelling by enhancement of the influence of ni-
tric oxide and the prevention from lipid insudation
into the vascular wall. Synthesis and release of BNP
is stimulated by mechanical stretching of the heart
chambers. A 134-amino acid prepropeptide is cut
into a precursor proBNP108, which is divided into
76-amino acid inactive NT-proBNP (plasma half-life
90–120 min) and BNP (plasma half-life 18 min). Its
biological activity is realised by binding with cell
receptors. It is eliminated via glomerular filtration
and endopeptidases. The elimination of NT-proBNP
has not been completely investigated [3].
In many cases, permanent cardiac pacing leads
to some side effects despite significant clinical im-
provement. One of the most explored aspects is the
development or aggravation of congestive heart fail-
ure (CHF) due to long-lasting right ventricular apex
pacing and the pathologic pathway of depolarisation
and intraventricular dyssynchrony [1, 4, 5]. Plasma
BNP measurement is a well-established diagnostic
and risk stratification tool in patients with CHF [6–8].
It is also very helpful in the monitoring of stable
patients. Assessment of BNP plasma levels in pa-
tients with permanent cardiac pacing has not been
widely explored, whereas in patients without pace-
makers it has.
The available publications on the influence of
permanent cardiac pacing on plasma BNP levels
consider comparisons of ventricular pacing mode
(VVI) to atrial (AAI) and dual-chamber pacing-mode
(DDD) [9–11]. In the last 10–15 years, the VVI
mode has become rare in patients with SSS as they
receive dual-chamber or atrial pacemakers. There-
fore, the assessment of plasma BNP during AAIR
or DDDR pacing modes in patients with SSS seems
to be reasonable.
Wang et al. [9] reported a significant increase
in BNP concentration during VVIR pacing in pa-
tients with SSS being in III or IV functional NYHA
class and with diminished left ventricular ejection
fraction. In contrast, dual-chamber pacing (DDDR)
in patients with SSS and impaired left ventricular
systolic function significantly decreased BNP lev-
els due to the restoration of atrio-ventricular syn-
chrony and an improvement in hemodynamics.
However, there were no significant changes in BNP
levels in patients with preserved left ventricular
function during both DDDR and VVIR pacing modes
in the nine-month follow-up. The results of the
study presented are convergent. There were no
significant changes in plasma BNP levels in patients
with preserved systolic left ventricular function
during the six-month follow-up. However, three
months after implantation an upward trend in BNP
levels with a tendency to decrease after the next
three months was noticed. An interesting observa-
tion is that in the DDD group BNP levels after six
months were slightly higher than the baseline. The
most probable reason for this finding is the pro-
longed pacing of the right ventricular apex and de-
polarisation pattern imitating left bundle branch
block resulting in ventricular dyssynchrony.
A similar tendency was noticed by Wang et al. in
patients with preserved systolic left ventricular func-
tion and VVIR pacing mode. A favourable, but not
significant, tendency in the neurohormonal profile in
the AAI group (decrease of BNP level to baseline)
resulted from the lack of right ventricular pacing.
The results of the presented study indicate that
in patients with SSS and preserved systolic left
ventricular function AAIR as well as DDDR pacing
Table 2. Changes in plasma BNP levels in the
AAI group and DDD group during six-month
follow-up.
AAI DDD
BNP0 [pg/mL] 94.05±54.1 73.57±70.1
BNP3 [pg/mL] 111.81±29.2 90.75±78.1
p — BNP0-3 > 0.5 (NS) > 0.5 (NS)
BNP6 [pg/mL] 82.94±79.9 82.39±58.9
p — BNP0-6 > 0.5 (NS) > 0.5 (NS)
BNP0, BNP3, BNP6 — plasma BNP levels before, three and six months
after implantation
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mode did not influence plasma BNP levels or left
atrial diameter. Despite activation of the available
algorithms of right ventricular pacing minimiza-
tion, the mean percentage of ventricular pacing
reached almost 60%. Surprisingly, there was no
significant increase in BNP levels. This finding
may explain the insignificant influence of perma-
nent cardiac pacing on long-term prognosis in pa-
tients with SSS [12–14].
An important clinical implication of research on
the influence of cardiac pacing on BNP release may
be its application for screening in patients with risk
factors of CHF (i.e. advanced age, atrial fibrillation,
prior myocardial infarction) including right ventricu-
lar pacing [1, 4, 11, 15–18]. Some authors claim that
BNP measurement during pacemaker follow-up is
justified for monitoring the severity of CHF [19],
and increased levels of BNP may indicate the need
of pharmacotherapy optimisation or upgrading the
pacing to the biventricular mode.
Limitations of the study
Small sample size, lack of randomization (due
to strict indications to definite pacing mode, fre-
quently established during procedure) and a limit-
ed length of follow-up do not really entitle us to
extrapolate trends in the general population.
Conclusions
Atrial (AAIR) and dual-chamber (DDDR) per-
manent cardiac pacing in patients with sick sinus
syndrome and preserved left ventricular systolic
function did not provoke any significant changes in
BNP plasma levels.
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